Eli Lilly looks like a solid long-term hold compared to Pfizer right now. Pfizer has been moving sideways since demand for their COVID vaccine dropped, but Lilly is expanding its pipeline with a recent $2.4 billion acquisition of Orna Therapeutics for gene editing tech. They also have new deals for immune and hearing loss treatments. Their drug tirzepatide is now the best-selling drug in the world, beating out Merck's Keytruda. LLY is up over 400% in the last five years and is getting close to a $1 trillion market cap.